Granulocyte Colony-Stimulating Factor (G-CSF): Clinical Use and Oncological Concerns
DOI:
https://doi.org/10.12775/QS.2026.54.70712Keywords
Granulocyte colony-stimulating factor, G-CSF, tumor aggressiveness, secondary malignancies, AML, MDSAbstract
Granulocyte colony-stimulating factor is a hematopoietic cytokine mainly produced by myeloid cells. Its primary role is to stimulate and promote neutrophil proliferation, which is commonly used in oncology to prevent myelosuppression often caused by cytotoxic treatment. Growing evidence suggests that its biological activity may extend beyond hematopoiesis and modulate tumor dynamics. Several studies indicate that elevated G-CSF levels and receptor expression are associated with greater aggressiveness and a more unfavourable prognosis. The role of G-CSF in fostering an immunosuppressive microenvironment, supporting metastasis, and promoting tumor growth has become a common area of research. Furthermore, studies have already claimed a higher incidence of secondary malignancies, like acute myeloid leukemia (AML) and myelodysplastic syndrome, among patients receiving G-CSF along with cytotoxic treatment.
References
1. Nagata S, Fukunaga R. Granulocyte colony-stimulating factor and its receptor. Prog Growth Factor Res. 1991;3(2):131-141. doi:10.1016/s0955-2235(05)80004-3
2. Schneider A, Krüger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115(8):2083-2098. doi:10.1172/JCI23559
3. Shimoji K, Yuasa S, Onizuka T, et al. G-CSF promotes the proliferation of developing cardiomyocytes in vivo and in derivation from ESCs and iPSCs. Cell Stem Cell. 2010;6(3):227-237. doi:10.1016/j.stem.2010.01.002
4. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. doi:10.1093/annonc/mdw325
5. Punnapuzha S, Edemobi PK, Elmoheen A. Febrile Neutropenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 30, 2023.
6. Gascón P, Awada A, Karihtala P, Lorenzen S, Minichsdorfer C. Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment : An expert view. Wien Klin Wochenschr. 2024;136(11-12):362-368. doi:10.1007/s00508-023-02300-6
7. Adamo V, Antonuzzo L, Danova M, et al. Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement. Support Care Cancer. 2022;30(12):9877-9888. doi:10.1007/s00520-022-07430-7
8. Ozaki Y, Yokoe T, Yoshinami T, et al. Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022. Int J Clin Oncol. 2024;29(5):551-558. doi:10.1007/s10147-024-02499-y
9. Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treat Rev. 2022;109:102427. doi:10.1016/j.ctrv.2022.102427
10. Asano S, Urabe A, Okabe T, Sato N, Kondo Y. Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood. 1977;49(5):845-852.
11. Schurmann G, Zweifel M, Giger R, et al. Granulocyte Colony-stimulating Factor Producing Oropharyngeal Squamous Cell Carcinoma. In Vivo. 2021;35(3):1785-1790. doi:10.21873/invivo.12438
12. Hirai K, Kumakiri M, Fujieda S, et al. Expression of granulocyte colony-stimulating factor and its receptor in epithelial skin tumors. J Dermatol Sci. 2001;25(3):179-188. doi:10.1016/s0923-1811(00)00131-6
13. Nagata H, Komatsu S, Takaki W, et al. Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes. World J Clin Oncol. 2016;7(5):380-386. doi:10.5306/wjco.v7.i5.380
14. Liu L, Liu Y, Yan X, Zhou C, Xiong X. The role of granulocyte colony‑stimulating factor in breast cancer development: A review. Mol Med Rep. 2020;21(5):2019-2029. doi:10.3892/mmr.2020.11017
15. Fan Z, Li Y, Zhao Q, et al. Highly Expressed Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte Colony-Stimulating Factor Receptor (G-CSFR) in Human Gastric Cancer Leads to Poor Survival. Med Sci Monit. 2018;24:1701-1711. Published 2018 Mar 23. doi:10.12659/msm.909128
16. Samejima H, Ose N, Sakurai T, Nagata H, Morii E, Shintani Y. G-CSF-producing left lung squamous cell carcinoma positive for ROS1 rearrangements completely resected after neoadjuvant radiation chemotherapy: A case report. Respir Med Case Rep. 2022;38:101697. Published 2022 Jun 27. doi:10.1016/j.rmcr.2022.101697
17. Shiba S, Oike T, Ando K, Yoshimoto Y, Takayama Y, Ohno T. Granulocyte-colony stimulating factor-producing uterine cervical cancer treated with chemoradiotherapy: A case report with mutation analysis and literature review. Clin Case Rep. 2020;9(1):185-192. Published 2020 Nov 6. doi:10.1002/ccr3.3495
18. Choi KJ, Kim KC, Kim EJ. A case of granulocyte colony-stimulating factor producing lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangements. Respir Med Case Rep. 2023;46:101885. Published 2023 Jun 5. doi:10.1016/j.rmcr.2023.101885
19. Morinaga R, Kawahara T, Kuroda S, Inayama Y, Uemura H. Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer. Case Rep Oncol. 2019;12(2):603-607. Published 2019 Aug 6. doi:10.1159/000502174
20. Kowanetz M, Wu X, Lee J, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A. 2010;107(50):21248-21255. doi:10.1073/pnas.1015855107
21. DuPre' SA, Hunter KW Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol. 2007;82(1):12-24. doi:10.1016/j.yexmp.2006.06.007
22. Abe F, Dafferner AJ, Donkor M, et al. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother. 2010;59(1):47-62. doi:10.1007/s00262-009-0719-2
23. Kawano M, Mabuchi S, Matsumoto Y, et al. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep. 2015;5:18217. Published 2015 Dec 15. doi:10.1038/srep18217
24. Paul MR, Huo Y, Liu A, et al. Characterization of G-CSF receptor expression in medulloblastoma. Neurooncol Adv. 2020;2(1):vdaa062. Published 2020 May 27. doi:10.1093/noajnl/vdaa062
25. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106(16):6742-6747. doi:10.1073/pnas.0902280106
26. Phan VT, Wu X, Cheng JH, et al. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A. 2013;110(15):6079-6084. doi:10.1073/pnas.1303302110
27. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(5):1161-1171. doi:10.1016/s0360-3016(01)01544-9
28. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076-13081. doi:10.1073/pnas.1200419109
29. Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446-3458. doi:10.1172/JCI67484
30. Hu W, Xu B, Zhang J, Kou L, Xu X. Neutrophil extracellular traps: biological functions and relevance in cancer metastasis and therapy. Signal Transduct Target Ther. 2022;7(1):305. doi:10.1038/s41392-022-01169-1
31. Poto R, Cristinziano L, Modestino L, et al. Neutrophil extracellular traps, angiogenesis and cancer. Biomedicines. 2022;10(2):431. doi:10.3390/biomedicines10020431
32. Xia X, Zhang Z, Zhu C, et al. Neutrophil extracellular traps promote metastasis in gastric cancer through TGF-β signaling. Nat Commun. 2022;13(1):4637. doi:10.1038/s41467-022-28492-5
33. Lyman GH, Yau L, Nakov R, Krendyukov A. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol. 2018;29(9):1903-1910. doi:10.1093/annonc/mdy311
34. Jabagi MJ, Vey N, Goncalves A, Le Tri T, Zureik M, Dray-Spira R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. Int J Cancer. 2021;148(2):375-384. doi:10.1002/ijc.33216
35. Calip GS, Moran KM, Sweiss KI, et al. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. Cancer. 2019;125(7):1143-1154. doi:10.1002/cncr.31914
36. Averin A, Silvia A, Lamerato L, et al. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer. 2021;29(4):2179-2186. doi:10.1007/s00520-020-05715-3
37. Link H, Kerkmann M, Holtmann L, Ortner P; Working Groups Supportive Care (ASORS now AGSMO) and Medical Oncology (AIO) within the German Cancer Society (DKG). G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer. 2019;27(4):1459-1469. doi:10.1007/s00520-018-4481-x
38. Barni S, Lorusso V, Giordano M, et al. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol. 2014;31(1):797. doi:10.1007/s12032-013-0797-z
39. Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 2014;3(6):1477-1484. doi:10.1002/cam4.344
40. Kumar A, Taghi Khani A, Sanchez Ortiz A, Swaminathan S. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Front Immunol. 2022;13:901277. Published 2022 Jul 5. doi:10.3389/fimmu.2022.901277
41. Elsayed A, Elsayed B, Elmarasi M, et al. Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review. Immunotargets Ther. 2024;13:461-486. Published 2024 Sep 13. doi:10.2147/ITT.S463384
42. McDermott DH, Velez D, Cho E, et al. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. J Clin Invest. 2023;133(19):e164918. Published 2023 Oct 2. doi:10.1172/JCI164918
43. Hughes JH, Tong DMH, Burns V, et al. Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning model. CPT Pharmacometrics Syst Pharmacol. 2023;12(11):1764-1776. doi:10.1002/psp4.13019
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Barbara Pietrzak, Mikołaj Patelski, Adrianna Klimczak, Wiktoria Kotlarz, Marta Kamińska, Matylda Kuczma, Jakub Molenda, Maciej Czapla, Mateusz Surma, Wiktoria Mikusek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 35
Number of citations: 0
